Lockheed Martin Declares Third Quarter 2023 Dividend

(Low)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

dividends earnings

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

06/22/2023 - 11:45 AM

BETHESDA, Md., June 22, 2023 /PRNewswire/ -- The Lockheed Martin Corporation (NYSE: LMT) board of directors has authorized a third quarter 2023 dividend of $3.00 per share. The dividend is payable on September 22, 2023, to holders of record as of the close of business on September 1, 2023.

About Lockheed Martin
Headquartered in Bethesda, Maryland, Lockheed Martin Corporation is a global security and aerospace company that employs approximately 116,000 people worldwide and is principally engaged in the research, design, development, manufacture, integration and sustainment of advanced technology systems, products and services.

Please follow @LMNews on Twitter for the latest announcements and news across the corporation.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lockheed-martin-declares-third-quarter-2023-dividend-301858284.html

SOURCE Lockheed Martin

Keep reading

More on LMT

Oct 9, 2026 Lockheed Martin Declares Fourth Quarter 2026 Dividend
Oct 9, 2026 Lockheed Martin Debuts PAC-3 Edge™ for the U.S. Army's Innovative Future Interceptor Program
Oct 5, 2026 Boeing receives seven-year contract to accelerate PAC-3 MSE seeker output

All LMT news

Trending in the feed

APUS

MindWave Innovations Signs 3 Client Network Agreements in 10 Days, Extending MindChain into Climate Finance, Sports Media and Insurance; Apimeds Pharmaceuticals US Provides Required NYSE American Disclosure Open the live feed